# Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis

> **NCT06095596** · NA · RECRUITING · sponsor: **Sixth Affiliated Hospital, Sun Yat-sen University** · enrollment: 334 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

- **DRUG:** Upadacitinib
- **DRUG:** Vedolizumab

## Key facts

- **NCT ID:** NCT06095596
- **Lead sponsor:** Sixth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2025-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 334 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06095596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06095596, "Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06095596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*